没有α-synuclein播种的帕金森病中的阿尔茨海默病特征
Bárbara Fernandes Gomes1, Carly M Farris2, Yihua Ma2
1Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
概括
阿尔法-同核素种子放大试验 (αSyn-SAA) 准确检测帕金森病 (PD),但在某些PD患者中可能是负面的. 这些阴性病例可能代表阿尔茨海默病 (AD) 的运动亚型.
科学领域:
- 神经科学
- 神经学
- 生物标志物发现
背景情况:
- 阿尔法-同核素 (αSyn) 种子放大试验 (αSyn-SAA) 是帕金森病 (PD) 的敏感诊断工具.
- 一部分临床诊断的PD患者在αSyn-SAA中呈现负面结果,需要对潜在病理进行进一步的研究.
研究的目的:
- 评估αSyn-SAA在各种神经退行性疾病中的诊断性能.
- 通过SAA对αSyn种子阴性的PD患者的临床和病理表型.
主要方法:
- 在患有PD (n=93),多种系统缩 (MSA,n=26),渐进性上核性 (PSP,n=18),皮质底部综合征 (n=3) 的患者的脑脊液 (CSF) 样本上进行了SAA.
- 在αSyn-SAA阳性和αSyn-SAA阴性PD患者中比较了临床表型和粉样蛋白β42水平.
主要成果:
- 在90%的PD患者和81%的MSA患者中检测到αSyn-SAA,其特异性为97%.
- αSyn-SAA阴性PD患者表现出明显的临床特征,包括更严重的姿势不稳定/ 走路障碍和情节性记忆障碍.
- 在αSyn-SAA阴性PD患者中观察到较低的粉样蛋白β42水平,SAA+PSP病例也表现出独特的特征.
结论:
- 患有PD的αSyn-SAA与特定的临床表现有关,并表明潜在的同时存在的阿尔茨海默病病理学.
- 这些发现强调阿尔茨海默病是运动障碍诊断的重要因素,并影响了阿尔茨海默病临床试验设计.
- αSyn-SAA是一种强大的测定方法,但其在某些PD病例中的局限性要求考虑AD等替代性或并发症.
相关概念视频
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Amyloid Fibrils
9.8K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.8K


